Meeting
2020 ASCO Virtual Scientific Program
Association of detectable levels of circulating tumor DNA (ctDNA) with disease burden in prostate cancer (PC).
Authors
Gerhardt Attard
University College London Cancer Institute, London, United Kingdom
Gerhardt Attard , Michael Gormley , Karen Urtishak , Jason S. Simon , Deborah S. Ricci , Trilok V. Parekh , Shinta Cheng , Kim N. Chi , Matthew Raymond Smith
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT02854436
Citation
J Clin Oncol 38: 2020 (suppl; abstr 5562)
DOI
10.1200/JCO.2020.38.15_suppl.5562
Abstract #
5562
Poster Bd #
143
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Evaluating early changes in circulating tumor DNA (ctDNA) tumor fraction (TF) as a value add to PSA in predicting early progression in metastatic castrate resistant prostate cancer (mCRPC).
First Author: Christopher Sweeney
Poster
2024 ASCO Genitourinary Cancers Symposium
Nucleosome profiling at AR binding sites (ARBS) to provide a prognostic tool for metastatic castration-resistant prostate cancer (mCRPC).
First Author: Chao Dai
Poster
2024 ASCO Genitourinary Cancers Symposium
Impact of race on outcomes to 177Lu-PSMA-617 (LuPSMA) for metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Avina Rami
Poster
2024 ASCO Genitourinary Cancers Symposium
Patient outcomes after therapy with 177Lu-PSMA-617 (LuPSMA) for metastatic castrate-resistant prostate cancer (mCRPC): A tertiary center experience.
First Author: Meryam Losee